Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 987,107
  • Shares Outstanding, K 47,230
  • Annual Sales, $ 840 K
  • Annual Income, $ -27,320 K
  • 36-Month Beta 1.29
  • Price/Sales 1,131.30
  • Price/Cash Flow N/A
  • Price/Book 5.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.94 +54.56%
on 03/28/18
22.00 -9.09%
on 04/23/18
+5.95 (+42.35%)
since 03/23/18
3-Month
10.50 +90.48%
on 02/15/18
22.00 -9.09%
on 04/23/18
+4.60 (+29.87%)
since 01/23/18
52-Week
4.55 +339.56%
on 06/16/17
22.75 -12.09%
on 10/11/17
+14.80 (+284.62%)
since 04/21/17

Most Recent Stories

More News
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation

ABEO : 20.00 (-4.31%)
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies...

ABEO : 20.00 (-4.31%)
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump

Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

BHVN : 28.50 (+4.86%)
ABEO : 20.00 (-4.31%)
Report: Exploring Fundamental Drivers Behind Haverty Furniture Companies, Scholastic, Dover, MYR Group, Abeona Therapeutics, and U.S. Global Investors -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haverty Furniture Companies,...

SCHL : 41.54 (-0.17%)
GROW : 2.95 (-2.64%)
MYRG : 30.94 (+0.39%)
ABEO : 20.00 (-4.31%)
HVT : 17.85 (unch)
DOV : 95.12 (-0.94%)
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

-- Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases

ABEO : 20.00 (-4.31%)
Abeona Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 27, 2018 / Abeona Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on March 27, 2018, at 10:00 AM Eastern Time....

ABEO : 20.00 (-4.31%)
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced...

ABEO : 20.00 (-4.31%)
New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Western Alliance Bancorporation...

WAL : 59.54 (+0.59%)
UAA : 16.73 (+3.91%)
ABEO : 20.00 (-4.31%)
AGNC : 18.79 (+0.70%)
MTN : 233.44 (+0.90%)
MATX : 29.18 (+0.21%)
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today...

ABEO : 20.00 (-4.31%)
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

- First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.

ABEO : 20.00 (-4.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 22.83
1st Resistance Point 21.42
Last Price 20.00
1st Support Level 19.17
2nd Support Level 18.33

See More

52-Week High 22.75
Last Price 20.00
Fibonacci 61.8% 15.80
Fibonacci 50% 13.65
Fibonacci 38.2% 11.50
52-Week Low 4.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar